-
1
-
-
85033517914
-
Bayesian extension of the minimum AIC procedure of autoregressive model fitting
-
Akaike, H. 1979. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242.
-
(1979)
Biometrika
, vol.66
, pp. 237-242
-
-
Akaike, H.1
-
2
-
-
24044460758
-
Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modeling
-
Cremers, S., R. Schoemaker, E. Scholten, J. den Hartigh, J. Konig-Quartel, E. van Kan, L. Paul, and J. de Fijter. 2005. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modeling. Br. J. Clin. Pharmacol. 60:249-256.
-
(2005)
Br. J. Clin. Pharmacol
, vol.60
, pp. 249-256
-
-
Cremers, S.1
Schoemaker, R.2
Scholten, E.3
den Hartigh, J.4
Konig-Quartel, J.5
van Kan, E.6
Paul, L.7
de Fijter, J.8
-
4
-
-
0018387530
-
A program package for simulation and parameter estimation in pharmacokinetic systems
-
D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134.
-
(1979)
Comput. Programs Biomed
, vol.9
, pp. 115-134
-
-
D'Argenio, D.Z.1
Schumitzky, A.2
-
6
-
-
10744226866
-
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir
-
Furfine, E. S., C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein. 2004. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48:791-798.
-
(2004)
Antimicrob. Agents Chemother
, vol.48
, pp. 791-798
-
-
Furfine, E.S.1
Baker, C.T.2
Hale, M.R.3
Reynolds, D.J.4
Salisbury, J.A.5
Searle, A.D.6
Studenberg, S.D.7
Todd, D.8
Tung, R.D.9
Spaltenstein, A.10
-
7
-
-
4644221931
-
Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients
-
Goujard, C., I. Vincent, J. L. Meynard, N. Choudet, D. Bollens, C. Rousseau, D. Demarles, C. Gillotin, R. Bidault, and A. M. Taburet. 2003. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 47:118-123.
-
(2003)
Antimicrob. Agents Chemother
, vol.47
, pp. 118-123
-
-
Goujard, C.1
Vincent, I.2
Meynard, J.L.3
Choudet, N.4
Bollens, D.5
Rousseau, C.6
Demarles, D.7
Gillotin, C.8
Bidault, R.9
Taburet, A.M.10
-
8
-
-
24944529235
-
Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions
-
Jeong, E. J., X. Liu, X. Jia, J. Chen, and M. Hu. 2005. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab. 6:455-468.
-
(2005)
Curr. Drug Metab
, vol.6
, pp. 455-468
-
-
Jeong, E.J.1
Liu, X.2
Jia, X.3
Chen, J.4
Hu, M.5
-
9
-
-
0003024589
-
Guidelines for collection and analysis of pharmacokinetic data
-
W. E. Evans, W. J. Jusko, and J. J. Schentag ed, 3rd ed. Applied Therapeutics, Washington, DC
-
Jusko, W. J. 1992. Guidelines for collection and analysis of pharmacokinetic data, p. 21-43. In W. E. Evans, W. J. Jusko, and J. J. Schentag (ed.), Applied pharmacokinetics, 3rd ed. Applied Therapeutics, Washington, DC.
-
(1992)
Applied pharmacokinetics
, pp. 21-43
-
-
Jusko, W.J.1
-
10
-
-
0038103536
-
Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8, ritonavir, and saquinavir in heparinized human plasma
-
Keil, K., V. A. Frerichs, R. DiFrancesco, and G. D. Morse. 2003. Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8, ritonavir, and saquinavir in heparinized human plasma. Ther. Drug Monit. 25:340-346.
-
(2003)
Ther. Drug Monit
, vol.25
, pp. 340-346
-
-
Keil, K.1
Frerichs, V.A.2
DiFrancesco, R.3
Morse, G.D.4
-
11
-
-
0034114537
-
Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats
-
Kuchimanchi, K. R., C. Udata, T. P. Johnston, and A. K. Mitra. 2000. Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats. Drug Metab. Dispos. 28:403-408.
-
(2000)
Drug Metab. Dispos
, vol.28
, pp. 403-408
-
-
Kuchimanchi, K.R.1
Udata, C.2
Johnston, T.P.3
Mitra, A.K.4
-
12
-
-
0242664896
-
Enteric disposition and recycling of flavonoids and ginkgo flavonoids
-
Liu, Y., Y. Liu, Y. Dai, L. Xun, and M. Hu. 2003. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J. Altern. Complement. Med. 9:631-640.
-
(2003)
J. Altern. Complement. Med
, vol.9
, pp. 631-640
-
-
Liu, Y.1
Liu, Y.2
Dai, Y.3
Xun, L.4
Hu, M.5
-
13
-
-
0036349377
-
Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications
-
Roberts, M. S., B. M. Magnusson, F. J. Burczynski, and M. Weiss. 2002. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41:751-790.
-
(2002)
Clin. Pharmacokinet
, vol.41
, pp. 751-790
-
-
Roberts, M.S.1
Magnusson, B.M.2
Burczynski, F.J.3
Weiss, M.4
-
14
-
-
0035180518
-
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
-
Sadler, B. M., C. Gillotin, Y. Lou, J. J. Eron, W. Lang, R. Haubrich, and D. S. Stein. 2001. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob. Agents Chemother. 45:3663-3668.
-
(2001)
Antimicrob. Agents Chemother
, vol.45
, pp. 3663-3668
-
-
Sadler, B.M.1
Gillotin, C.2
Lou, Y.3
Eron, J.J.4
Lang, W.5
Haubrich, R.6
Stein, D.S.7
-
15
-
-
0035174709
-
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
-
Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45:30-37.
-
(2001)
Antimicrob. Agents Chemother
, vol.45
, pp. 30-37
-
-
Sadler, B.M.1
Gillotin, C.2
Lou, Y.3
Stein, D.S.4
-
16
-
-
0032779413
-
Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
-
Sadler, B. M., C. D. Hanson, G. E. Chittick, W. T. Symonds, and N. S. Roskell. 1999. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother. 43:1686-1692.
-
(1999)
Antimicrob. Agents Chemother
, vol.43
, pp. 1686-1692
-
-
Sadler, B.M.1
Hanson, C.D.2
Chittick, G.E.3
Symonds, W.T.4
Roskell, N.S.5
-
17
-
-
33745448252
-
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics
-
Shelton, M. J., S. L. Ford, J. Borland, Y. Lou, M. B. Wire, S. S. Min, Z. G. Xue, and G. Yuen. 2006. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J. Acquir. Immune Defic. Syndr. 42:61-67.
-
(2006)
J. Acquir. Immune Defic. Syndr
, vol.42
, pp. 61-67
-
-
Shelton, M.J.1
Ford, S.L.2
Borland, J.3
Lou, Y.4
Wire, M.B.5
Min, S.S.6
Xue, Z.G.7
Yuen, G.8
-
18
-
-
33644645264
-
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir
-
Shelton, M. J., M. B. Wire, Y. Lou, B. Adamkiewicz, and S. S. Min. 2006. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob. Agents Chemother. 50:928-934.
-
(2006)
Antimicrob. Agents Chemother
, vol.50
, pp. 928-934
-
-
Shelton, M.J.1
Wire, M.B.2
Lou, Y.3
Adamkiewicz, B.4
Min, S.S.5
-
19
-
-
23844526234
-
Population pharmacokinetic modeling for enterohepatic recirculation in rhesus monkey
-
Shou, M., W. Lu, P. H. Kari, C. Xiang, Y. Liang, P. Lu, D. Cui, W. B. Emary, K. B. Michel, J. K. Adelsberger, J. E. Brunner, and A. D. Rodrigues. 2005. Population pharmacokinetic modeling for enterohepatic recirculation in rhesus monkey. Eur. J. Pharm. Sci. 26:151-161.
-
(2005)
Eur. J. Pharm. Sci
, vol.26
, pp. 151-161
-
-
Shou, M.1
Lu, W.2
Kari, P.H.3
Xiang, C.4
Liang, Y.5
Lu, P.6
Cui, D.7
Emary, W.B.8
Michel, K.B.9
Adelsberger, J.K.10
Brunner, J.E.11
Rodrigues, A.D.12
-
20
-
-
0021277886
-
Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed-effect model
-
Steimer, J. L., A. Mallet, J. L. Golmard, and J. F. Boisvieux. 1984. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab. Rev. 15:265-292.
-
(1984)
Drug Metab. Rev
, vol.15
, pp. 265-292
-
-
Steimer, J.L.1
Mallet, A.2
Golmard, J.L.3
Boisvieux, J.F.4
-
21
-
-
0034020556
-
Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function
-
Veronese, L., J. Rautaureau, B. M. Sadler, C. Gillotin, J.-P. Petite, B. Pillegand, M. Delvaux, C. Masliah, S. Fosse, Y. Lou, and D. S. Stein. 2000. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob. Agents Chemother. 44:821-826.
-
(2000)
Antimicrob. Agents Chemother
, vol.44
, pp. 821-826
-
-
Veronese, L.1
Rautaureau, J.2
Sadler, B.M.3
Gillotin, C.4
Petite, J.-P.5
Pillegand, B.6
Delvaux, M.7
Masliah, C.8
Fosse, S.9
Lou, Y.10
Stein, D.S.11
-
22
-
-
0004580383
-
A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration
-
Wang, Y., A. Roy, L. Sun, and C. E. Lau. 1999. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab. Dispos. 27:855-859.
-
(1999)
Drug Metab. Dispos
, vol.27
, pp. 855-859
-
-
Wang, Y.1
Roy, A.2
Sun, L.3
Lau, C.E.4
-
23
-
-
33645789309
-
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV
-
Wire, M. B., K. L. Baker, L. S. Jones, M. J. Shelton, Y. Lou, G. J. Thomas, and M. M. Berrey. 2006. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob. Agents Chemother. 50:1578-1580.
-
(2006)
Antimicrob. Agents Chemother
, vol.50
, pp. 1578-1580
-
-
Wire, M.B.1
Baker, K.L.2
Jones, L.S.3
Shelton, M.J.4
Lou, Y.5
Thomas, G.J.6
Berrey, M.M.7
-
24
-
-
33344460707
-
Fosamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug
-
Wire, M. B., M. J. Shelton, and S. Studenberg. 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45:137-168.
-
(2006)
Clin. Pharmacokinet
, vol.45
, pp. 137-168
-
-
Wire, M.B.1
Shelton, M.J.2
Studenberg, S.3
|